AR057643A1 - LACOSAMIDE FOR ATTACHED THERAPY - Google Patents

LACOSAMIDE FOR ATTACHED THERAPY

Info

Publication number
AR057643A1
AR057643A1 ARP060100304A ARP060100304A AR057643A1 AR 057643 A1 AR057643 A1 AR 057643A1 AR P060100304 A ARP060100304 A AR P060100304A AR P060100304 A ARP060100304 A AR P060100304A AR 057643 A1 AR057643 A1 AR 057643A1
Authority
AR
Argentina
Prior art keywords
lacosamide
therapy
attached
attached therapy
antipsychotics
Prior art date
Application number
ARP060100304A
Other languages
Spanish (es)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR057643A1 publication Critical patent/AR057643A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de una clase de compuestos péptidos para la prevencion, alivio y/o tratamiento de una enfermedad tratada con antipsicoticos, en particular psicosis, más particularmente, esquizofrenia, en una terapia adjunta a al menos un antipsicotico.Use of a class of peptide compounds for the prevention, relief and / or treatment of a disease treated with antipsychotics, in particular psychosis, more particularly, schizophrenia, in a therapy attached to at least one antipsychotic.

ARP060100304A 2005-01-28 2006-01-27 LACOSAMIDE FOR ATTACHED THERAPY AR057643A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
AR057643A1 true AR057643A1 (en) 2007-12-12

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100304A AR057643A1 (en) 2005-01-28 2006-01-27 LACOSAMIDE FOR ATTACHED THERAPY

Country Status (12)

Country Link
EP (1) EP1841417A2 (en)
JP (1) JP2008528532A (en)
KR (1) KR20070096058A (en)
AR (1) AR057643A1 (en)
AU (1) AU2006208630B2 (en)
BR (1) BRPI0607043A2 (en)
CA (1) CA2595330A1 (en)
EA (1) EA015566B1 (en)
IL (1) IL183973A0 (en)
MX (1) MX2007009070A (en)
NO (1) NO20074361L (en)
WO (1) WO2006079547A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (en) 2006-06-15 2014-03-12 优时比制药有限公司 Pharmaceutical composition with synergistic anticonvulsant effect
US8735356B2 (en) * 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
WO2010077916A1 (en) * 2008-12-16 2010-07-08 Eurand, Inc. Compositions comprising melperone
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP3766485A1 (en) 2010-12-02 2021-01-20 UCB Pharma GmbH Once daily formulation of lacosamide
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
MX2020005517A (en) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Crystal forms and production methods thereof.
CN112118838A (en) 2017-12-05 2020-12-22 赛诺维信制药公司 Non-racemic mixtures and uses thereof
KR20210022656A (en) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 Transdermal treatment system containing acenapine
JP2022535893A (en) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク MODIFIED RELEASE FORMULATIONS AND THEIR USE
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Also Published As

Publication number Publication date
JP2008528532A (en) 2008-07-31
AU2006208630A1 (en) 2006-08-03
MX2007009070A (en) 2007-09-12
WO2006079547A3 (en) 2006-09-21
EA015566B1 (en) 2011-10-31
BRPI0607043A2 (en) 2009-08-04
WO2006079547A2 (en) 2006-08-03
KR20070096058A (en) 2007-10-01
AU2006208630B2 (en) 2011-09-29
NO20074361L (en) 2007-10-26
IL183973A0 (en) 2008-12-29
EP1841417A2 (en) 2007-10-10
CA2595330A1 (en) 2006-08-03
EA200701594A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
AR057643A1 (en) LACOSAMIDE FOR ATTACHED THERAPY
NL300936I2 (en) Semaglutide
CY1122522T1 (en) META ARSENICODE SODIUM FOR USE IN THE MANAGEMENT OF MULTIPLE MYELOMA
NO20053051D0 (en) Fatigue reducing agent.
CL2007002327A1 (en) COMPOUNDS DERIVED FROM REPLACED FENIL-IMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF HCV.
UA94221C2 (en) Lipocalin protein
PA8637301A1 (en) DERIVATIVES OF AMINO-5, 5-DIFENYLIMIDAZOLONE FOR THE INHIBITION OF THE B-SECRETASE
CL2007002384A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of psoriasis.
PA8637201A1 (en) DIFENYLIMIDAZOPIRIMIDINE E-IMIDAZOL AMINAS AS INHIBITORS OF B-SECRETASE
CL2009001099A1 (en) Use of a human interleukin-2 mutein for the treatment and / or prevention of an autoimmune disease.
ATE481984T1 (en) VACCINE-PEPTIDE COMBINATIONS AGAINST CAT ALLERGY
CL2008000910A1 (en) Fusion protein comprising a protein that cuts the beta amyloid peptide; pharmaceutical composition that includes it, and its use to prevent and / or treat diseases related to beta amyloid peptide.
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
AR058173A1 (en) USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.
FR2864552B1 (en) SURFACE TREATMENT WITH HYDROXYSULFATE
CL2007002380A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the therapeutic and / or prophylactic treatment of actinic keratosis.
TW200637538A (en) Lacosamide for add-on-therapy
UY29417A1 (en) ENDOPARASITICID AGENTS
UY28344A1 (en) NEW COMPOUNDS
DK1838716T3 (en) Olanzapinpamota dihydrate
CL2008000865A1 (en) COMPOUNDS DERIVED FROM BENZIMIDAZOL-2-ONA; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF A PSYCHOTIC DISORDER OR A COGNITIVE DETERIORATION.
DE10394003D2 (en) Textile treatment agents
DE60322942D1 (en) TEXTILE TREATMENT
RU2005119153A (en) MEANS OF TREATMENT OF ACUTE RADIATING DISEASE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal